Monitoring and mitigating client-side exploitation of application flaws
US-2015249678-A1 · Sep 3, 2015 · US
US2022010029A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2022010029-A1 |
| Application number | US-202117368108-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jul 6, 2021 |
| Priority date | Jul 8, 2020 |
| Publication date | Jan 13, 2022 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A hybridoma cell strain secreting anti-dinitolmide monoclonal antibodies deposited at China General Microbiological Culture Collection Center (CGMCC) at No. 1 West Beichen Road, Chaoyang District, Beijing 100101, China on Nov. 28, 2019, with deposit number of CGMCC No. 19165. It is classified as a monoclonal cell strain. The monoclonal antibody secreted by the hybridoma cell strain DAS3H10 has a good affinity and high sensitivity to dinitolmide. Because of IC 50 to dinitolmide up to 9.01 ng/mL, the monoclonal antibody could be used to prepare dinitolmide immunoassay kit and colloidal gold test strip and provides a powerful detection method and means for the detection of dinitolmide in animal-derived foods.
Opening claim text (preview).
What is claimed is: 1 . A hybridoma cell strain secreting anti-dinitolmide monoclonal antibodies and deposited at China General Microbiological Culture Collection Center (CGMCC) at No. 1 West Beichen Road, Chaoyang District, Beijing 100101, China on Nov. 28, 2019, with deposit number of CGMCC No. 19165. 2 . Anti-dinitolmide monoclonal antibody secreted by the hybridoma cell strain of claim 1 . 3 . A method of making complete immunogen of dinitolmide comprising the following steps: dissolving 4.5 mg of 3,5-dinitro-2-methylbenzoic acid, as well as 5.0 mg EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) and 3.7 mg NHS (N-hydroxyamide) in DMF (N,N-dimethylformamide), stirring and activating at room temperature for 6 hour to obtain an activated solution; dissolving another 15 mg BSA(bovine serum protein) in 3 mL, 0.05M, pH 9.6 carbonate buffer solution; adding the activated solution dropwise to the BSA solution, stirring at room temperature overnight, and then taking out immunogen and dialyzing with PBS for 3 days; and storing the immunogen by aliquoted storage at −20° C. and obtaining the complete immunogen of dinitolmide. 4 . A method of detecting dinitolmide residues in food comprising applying the anti-dinitrotoamine monoclonal antibody of claim 2 to food and detecting dinitolmide residues in food based on the interaction of the anti-dinitrotoamine monoclonal antibody with the food.
for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites · CPC title
involving narcotics {or drugs or pharmaceuticals, neurotransmitters or associated receptors} · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title
Porphyrin- or corrin-ring-containing peptides · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.